Next Article in Journal
Longitudinal Assessment of Antimicrobial Susceptibility among Gram-Negative and Gram-Positive Organisms Collected from Italy as Part of the Tigecycline Evaluation and Surveillance Trial between 2004 and 2011
Next Article in Special Issue
Glioblastoma Multiforme Therapy and Mechanisms of Resistance
Previous Article in Journal
Metabolic Interactions of Purine Derivatives with Human ABC Transporter ABCG2: Genetic Testing to Assess Gout Risk
Previous Article in Special Issue
Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
Pharmaceuticals 2013, 6(11), 1361-1380; doi:10.3390/ph6111361
Review

Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes

1
 and
2,*
Received: 12 September 2013 / Revised: 24 October 2013 / Accepted: 28 October 2013 / Published: 4 November 2013
(This article belongs to the Special Issue Chemotherapeutic Agents)
View Full-Text   |   Download PDF [468 KB, uploaded 4 November 2013]   |   Browse Figure

Abstract

Nanomedicine is a growing research field dealing with the creation and manipulation of materials at a nanometer scale for the better treatment, diagnosis and imaging of diseases. In cancer medicine, the use of nanoparticles as drug delivery systems has advanced the bioavailability, in vivo stability, intestinal absorption, solubility, sustained and targeted delivery, and therapeutic effectiveness of several anticancer agents. The expansion of novel nanoparticles for drug delivery is an exciting and challenging research filed, in particular for the delivery of emerging cancer therapies, including small interference RNA (siRNA) and microRNA (miRNAs)-based molecules. In this review, we focus on the currently available drug delivery systems for anticancer agents. In addition, we will discuss the promising use of nanoparticles for novel cancer treatment strategies.
Keywords: nanoparticles; nanoliposomes; RNAi; miRNA; siRNA nanoparticles; nanoliposomes; RNAi; miRNA; siRNA
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Díaz, M.R.; Vivas-Mejia, P.E. Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes. Pharmaceuticals 2013, 6, 1361-1380.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert